2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Omics Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Infectious Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

4043 Matching-adjusted indirect comparisons (MAICs) of efficacy and safety outcomes for anitocabtagene autoleucel versus ciltacabtagene autoleucel in 4L+ relapsed and/or refractory multiple myeloma (RRMM): Analysis with extended iMMagine-1 follow-up

Surbhi Sidana, MD, Thomas Martin, MD2, Jie Ting, PhD, MSPH3, Ken Hasegawa, PhD4, Ana Kostic, MD5, Kamalika Banerjee, MS6, Rebecca Chan, MD, PhD7, Priyam Mitra, PhD8, Brett Doble9, Julia Thornton Snider, PhD10, Monique Giordana, PharmD11, Evan Popoff12, Ke Zhang, PhD13, Steve Kanters, PhD14, Maria-Victoria Mateos Jr, MD, PhD15, Krina Patel Jr, MD, MSc16
1 Stanford School of Medicine, Palo Alto, California, United States
2 University of California, San Francisco, California, United States
3 Arcellx, Redwood City, California, United States
4 Kite Pharma, a Gilead Company, Santa Monica, California, United States
5 Arcellx, Redwood City, California, United States
6 Arcellx, Redwood City, California, United States
7 Arcellx, Redwood City, California, United States
8 Arcellx, Redwood City, California, United States
9 Kite Pharma, a Gilead Company, Santa Monica, California, United States
10 Kite Pharma, a Gilead Company, Santa Monica, California, United States
11 Kite Pharma, a Gilead Company, Santa Monica, California, United States
12 RainCity Analytics Inc, Vancouver, British Columbia, Canada
13 RainCity Analytics Inc, Vancouver, British Columbia, Canada
14 RainCity Analytics Inc, Vancouver, British Columbia, Canada
15 University Hospital of Salamanca-IBSAL-CIC-CIBERONC, Salamanca, Spain
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Introduction: BCMA-directed chimeric antigen receptor (CAR) T-cell therapies have improved outcomes for patients with RRMM after ≥3 prior lines of therapy (4L+). iMMagine-1 and CARTITUDE-1 assessed anito-cel and cilta-cel, respectively, in 4L+ RRMM; cilta-cel, the leading commercially available BCMA CAR T-cell therapy, was selected for the MAIC with anito-cel. MAICs evaluated response, time-to-event (TTE), and safety outcomes between anito-cel and cilta-cel at 18-month median follow-up (mFU).

Methods: Unanchored MAICs used iMMagine-1 individual patient-level data (efficacy evaluable population; N=117; mFU=18 months) and published aggregate CARTITUDE-1 data (N=97; mFU=18 months). To account for between-trial differences in patient characteristics, the primary analyses adjusted for high-priority prognostic factors identified via systematic review and expert physician consultation: extramedullary disease, cytogenetic risk, refractory status, revised international staging system, and % bone marrow plasma cells (BMPC) for efficacy; and ECOG status, % BMPC, age, and sex for safety. Sensitivity analyses adjusted for lower-priority prognostic factors. For TTE outcomes, treatment effects were estimated using hazard ratios (HR), while odds ratios (OR) were used to estimate treatment effects for response and safety endpoints. For the latter, risk differences (RD) and relative risks (RR) used when zero or 100% event rates occurred in either study, respectively.

Results: Effective sample sizes for efficacy and safety primary analyses were 102 and 106, respectively (representing 87% and 91% of iMMagine-1 sample size), indicating substantial overlap in patient characteristics between trials.

After adjusting for baseline differences, progression-free survival (PFS) did not differ significantly between anito-cel and cilta-cel treated populations (HR: 0.89; 95% confidence interval [CI]: 0.55-1.44; proportional hazards assumption held). Similarly, overall response rates were high and did not differ significantly between anito-cel and cilta-cel (96% vs. 98%; OR: 0.33; 95% CI: 0.06-1.85). Complete response or better were likewise similar (75% vs 78%; OR: 0.79; 95% CI: 0.41-1.54). Efficacy results were consistent across sensitivity analyses.

Anito-cel was associated with significantly lower odds of key safety events compared with cilta-cel, specifically any-grade cytokine release syndrome (CRS, anito-cel vs cilta-cel: 85% vs 95%; OR: 0.33; 95% CI: 0.11-0.94), any-grade immune effector cell-associated neurotoxicity syndrome (ICANS, 8% vs 23%; OR: 0.28; 95% CI: 0.12-0.67), grade 3-4 infections (9% vs 23%; OR: 0.28; 95% CI: 0.12-0.66), and non-relapse mortality (NRM; 3% vs 11%; OR: 0.20; 95% CI: 0.06-0.68). Although all patients experienced at least one adverse event, grade ≥3 adverse events occurred significantly less frequently with anito-cel than cilta-cel (85% vs 100%; RR: 0.85; 95% CI: 0.79-0.92). No non-ICANS neurotoxicity events were observed with anito-cel in iMMagine-1, compared with 12 events with cilta-cel in CARTITUDE-1. Notably, anito-cel was associated with a significantly lower risk of any-grade Parkinsonism, with no events reported vs 5 events in cilta-cel (RD: -5.15%; 95% CI: -9.60%, -0.71%). Other safety endpoints analyzed, including grade ≥3 CRS (0.9% vs 5%; OR: 0.12; 95% CI: 0.01-1.08), grade ≥3 ICANS (0.9% vs 5%; OR: 0.12; 95% CI: 0.01-1.04), and any-grade infections (56% vs 59%; OR: 0.91; 95% CI: 0.52-1.60) did not differ significantly between trials. Safety results were consistent across sensitivity analyses.

Conclusions: After adjusting for prognostic factors, anito‑cel demonstrated a comparable efficacy profile to cilta-cel in PFS and response outcomes. Anito-cel also showed a superior safety profile in patients with RRMM treated in the 4L+ setting, with clinically meaningful reductions in any-grade CRS and ICANS, grade 3-4 infections, and NRM. Notably, there were no non-ICANS neurotoxicity events reported in iMMagine-1. Given that toxicity management is a major driver of healthcare resource use in CAR T-cell therapy, reduced toxicity may enable shorter hospital stays, lower resource utilization, and greater feasibility of outpatient and community-based administration, ultimately improving system capacity and patient access. 

Surbhi Sidana, MD: Janssen, BMS, Legend, Arcellx, Kite, Genentech, Roche, Sanofi, Pfizer, Takeda, Kite, Bioline, AbbVie, Cell Centric, Caribou, Regeneron and Eli Lilly (conuslting). Research funding to insitution: Janssen, BMS, Kite, Kelonia, Novartis, Abbvie - Consultancy (Includes expert testimony)